Literature DB >> 22660965

Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.

Fumi Kobayashi1, Shuhei Yamada, Shuhei Taguwa, Chikako Kataoka, Satomi Naito, Yoshiki Hama, Hideki Tani, Yoshiharu Matsuura, Kazuyuki Sugahara.   

Abstract

The first step in the process of infections by the hepatitis C virus (HCV) is attachment to the host cell, which is assumed to be mediated by interaction of the envelope glycoproteins E1 and E2 with cell surface glycosaminoglycans. In this study, a variety of glycosaminoglycans, heparan sulfate (HS) from various bovine tissues as well as chondroitin sulfate (CS)/dermatan sulfate from bovine liver, were used to examine the direct interaction with recombinant E1 and E2 proteins. Intriguingly, among HS preparations from various bovine tissues, only liver HS strongly bound to both E1 and E2. Since HS from liver, which is the target tissue of HCV, contains highly sulfated structures compared to HS from other tissues, the present results suggest that HS-proteoglycan on the liver cell surface appears to be one of the molecules that define the liver-specific tissue tropism of HCV infection. The interaction assay with chemically modified heparin derivatives provided evidence that the binding of the viral proteins to heparin/HS is not only mediated by simple ionic interactions, but that the 6-O-sulfation and N-sulfation are important. Heparin oligosaccharides equal to or larger than 10-mer were required to inhibit the binding. Notably, a highly sulfated CS-E preparation from squid cartilage also strongly interacted with both viral proteins and inhibited the entry of pseudotype HCV into the target cells, suggesting that the highly sulfated CS-E might be useful as an anti-HCV drug.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22660965     DOI: 10.1007/s10719-012-9388-z

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  53 in total

1.  Microanalysis of glycosaminoglycan-derived oligosaccharides labeled with a fluorophore 2-aminobenzamide by high-performance liquid chromatography: application to disaccharide composition analysis and exosequencing of oligosaccharides.

Authors:  A Kinoshita; K Sugahara
Journal:  Anal Biochem       Date:  1999-05-01       Impact factor: 3.365

2.  Novel 70-kDa chondroitin sulfate/dermatan sulfate hybrid chains with a unique heterogeneous sulfation pattern from shark skin, which exhibit neuritogenic activity and binding activities for growth factors and neurotrophic factors.

Authors:  Chilkunda D Nandini; Nobuyuki Itoh; Kazuyuki Sugahara
Journal:  J Biol Chem       Date:  2004-11-19       Impact factor: 5.157

3.  Suramin blocks hepatitis C binding to human hepatoma cells in vitro.

Authors:  J A Garson; D Lubach; J Passas; K Whitby; P R Grant
Journal:  J Med Virol       Date:  1999-03       Impact factor: 2.327

Review 4.  Potential therapeutic application of chondroitin sulfate/dermatan sulfate.

Authors:  Shuhei Yamada; Kazuyuki Sugahara
Journal:  Curr Drug Discov Technol       Date:  2008-12

5.  Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Authors:  Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

6.  Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.

Authors:  Bowen Liu; Shirish Paranjpe; William C Bowen; Aaron W Bell; Jian-Hua Luo; Yan-Ping Yu; Wendy M Mars; George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

7.  Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.

Authors:  Heidi Barth; Eva K Schnober; Fuming Zhang; Robert J Linhardt; Erik Depla; Bertrand Boson; Francois-Loic Cosset; Arvind H Patel; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

8.  A genetically humanized mouse model for hepatitis C virus infection.

Authors:  Marcus Dorner; Joshua A Horwitz; Justin B Robbins; Walter T Barry; Qian Feng; Kathy Mu; Christopher T Jones; John W Schoggins; Maria Teresa Catanese; Dennis R Burton; Mansun Law; Charles M Rice; Alexander Ploss
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 9.  Interactions between heparan sulfate and proteins: the concept of specificity.

Authors:  Johan Kreuger; Dorothe Spillmann; Jin-ping Li; Ulf Lindahl
Journal:  J Cell Biol       Date:  2006-07-31       Impact factor: 10.539

10.  Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.

Authors:  Hideki Tani; Yasumasa Komoda; Eiko Matsuo; Kensuke Suzuki; Itsuki Hamamoto; Tetsuo Yamashita; Kohji Moriishi; Kazuhito Fujiyama; Tatsuya Kanto; Norio Hayashi; Ania Owsianka; Arvind H Patel; Michael A Whitt; Yoshiharu Matsuura
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

View more
  8 in total

1.  Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection.

Authors:  Atsushi Tanaka; Uranan Tumkosit; Shota Nakamura; Daisuke Motooka; Natsuko Kishishita; Thongkoon Priengprom; Areerat Sa-Ngasang; Taroh Kinoshita; Naokazu Takeda; Yusuke Maeda
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  2-O-Sulfated Domains in Syndecan-1 Heparan Sulfate Inhibit Neutrophil Cathelicidin and Promote Staphylococcus aureus Corneal Infection.

Authors:  Atsuko Hayashida; Shiro Amano; Richard L Gallo; Robert J Linhardt; Jian Liu; Pyong Woo Park
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

Review 3.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.

Authors:  Jason Alexander Ji-Xhin Wong; Rakesh Bhat; Darren Hockman; Michael Logan; Chao Chen; Aviad Levin; Sharon E Frey; Robert B Belshe; D Lorne Tyrrell; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

5.  Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.

Authors:  Jannick Prentoe; Stéphanie B N Serre; Santseharay Ramirez; Alfredo Nicosia; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

6.  Role of glycosaminoglycans in infectious disease.

Authors:  Akiko Jinno; Pyong Woo Park
Journal:  Methods Mol Biol       Date:  2015

Review 7.  Glycosaminoglycans and infection.

Authors:  Rafael S Aquino; Pyong Woo Park
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

Review 8.  Diversity of heparan sulfate and HSV entry: basic understanding and treatment strategies.

Authors:  Vaibhav Tiwari; Morgan S Tarbutton; Deepak Shukla
Journal:  Molecules       Date:  2015-02-05       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.